Zynerba Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Vicinity Motor Corp (CVE:VMC) (OTCQX:BUSXF) (FRA:6LG) reported a 588% year-over-year increase in its first quarter 2021 revenue to C$27.3 million as the company delivered 67 buses during the period, about 10 times more than a year ago. Vicinity also swung to a quarterly profit $2.0 million, or $0.07 per share, from a net loss of $1.7 million, or $0.07 per share, in the same quarter a year earlier.
Midwest Energy Emissions Corp (OTCQB:MEEC) (ME2C Environmental) reported its 1Q results showing a 171% bump in year-over-year revenue at $3 million for the quarter. The environmental technologies firm saw most of its revenue come from sorbent product sales, which hit $2 million. During the three-month period to end March 31, 2021, ME2C strengthened its balance sheet by eliminating $1.85 million in convertible debt.
Lead development candidate Zygel offers a potential goldmine of therapies for multiple conditions
Zygel is being developed for patients suffering from Fragile X syndrome, a genetic condition that causes learning disabilities
What Zynerba does:
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is doing trailblazing work pushing clinical trials for cannabis-derived treatments. The specialty pharma company is developing novel transdermal CBD treatments for patients suffering rare epilepsies and neurological disorders.
The Devon, Pennsylvania-based company’s main product candidate is Zygel, a patent-protected CBD skin gel, which was earlier known as ZYNOO2.
Recent studies have suggested that neuropsychiatric conditions like Fragile X Syndrome the most common form of inherited learning disability and attention deficit disorder are associated with a disruption in the endocannabinoid system, and CBD may improve certain core social and behavioral symptoms by modulating the biol
Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights - read this article along with other careers information, tips and advice on BioSpace